climbed Tuesday after the company reported better-than-expected results for the fourth quarter.
Earnings, excluding special items, of 27 cents a share beat the Wall Street consensus by 3 cents. The stock rose $1.12, or 5.4%, by early afternoon. Schering-Plough didn't make predictions about the first quarter or the full year.
On a GAAP basis, the October-to-December quarter was affected by $3.81 billion in net charges related to its Nov. 19 acquisition of Organon BioSciences from
When all special items are included, Schering-Plough lost $3.4 billion, or $2.08 a share, on revenue of $3.72 billion. The revenue figure includes six weeks' worth of Organon sales commencing from the day the deal closed. Analysts polled by Thomson First Call had been forecasting sales of $3.1 billion. For the fourth quarter of 2006, the company earned $182 million, or 12 cents a share, on sales of $2.65 million.
The GAAP numbers exclude sales from Schering-Plough's joint venture with
(MRK - Get Report)
to sell the cholesterol drugs Vytorin and Zetia. Vytorin is a combination pill containing Schering-Plough's Zetia and Merck's Zocor. The cholesterol franchise is Schering-Plough's biggest source of profit, and the company's 50% share of the joint venture means these drugs added $722 million to fourth-quarter sales.
Fourth-quarter results were unaffected by the ongoing controversy over the publication of a Vytorin clinical trial. Preliminary test results were released in mid-January -- a more detailed account is expected in March -- amid a chorus of medical critics' and legislators' questions about the test. The last patient visit for the test took place in April 2006. Schering-Plough says the results were first made available to a "small group of scientists" on Dec. 31.
Prescriptions for Vytorin and Zetia have been hurt since the results were revealed. Many analysts have reduced their cholesterol franchise revenue expectations, even though they say they believe legislators, doctors and patients have overreacted to the Vytorin news. After the test was made public, Schering-Plough's stock was pounded, provoking some analysts to recommend buying the shares on what they believe is a temporary weakness.
The two companies "acted with integrity and good faith with respect to that trial," Fred Hassan, the chairman and CEO of Schering-Plough, said Tuesday. "We stand behind Vytorin and Zetia [and] behind the validity of the science."
The clinical trial, called ENHANCE, sought to determine if Vytorin was better at reducing the thickening of certain arteries vs. Zetia alone. The test examined 720 patients with a rare condition that produces high levels of so-called bad cholesterol, which cardiologists say is a warning signal for heart disease.
The test found no statistically significant difference between the two drugs in terms of artery thickening, an indicator of heart-disease risk. Vytorin was significantly better in reducing bad cholesterol.
"Medical experts and health advisory groups have long recognized" that bad cholesterol, also known as LDL cholesterol, is a "significant cardiovascular risk factor," the company said Tuesday.
"While it is too early to tell the impact of the ENHANCE trial results on [our] cholesterol business, lowering LDL cholesterol, along with healthy diet and lifestyle changes," is crucial for patients with a heart-disease risk, the company said.
Cholesterol-fighting has been big for Schering-Plough and Merck. The $722 million representing Schering-Plough's fourth-quarter sales share was 33% more than the fourth quarter of 2006. Its full-year share, worth $2.56 billion, rose 34% over the previous year.
The cholesterol franchise accounts for 17% of what Schering-Plough calls adjusted net sales, or GAAP revenue plus joint venture revenue. Analysts say Zetia and Vytorin account for 60% or more of Schering-Plough's earnings per share.